Canakinumab for first line steroid-free treatment in a child with systemic-onset juvenile idiopathic arthritis

Scand J Rheumatol. 2017 Nov;46(6):500-501. doi: 10.1080/03009742.2017.1288827. Epub 2017 Mar 7.

Authors

G Horneff¹, J Peitz¹, J Kekow², D Foell³

Affiliations

¹ a Department of Paediatrics and Neonatology , Asklepios Clinics , Sankt Augustin , Germany.
² b HELIOS Specialist Clinic , Vogelsang-Gommern , Gommern , Germany.
³ c Department of Paediatric Rheumatology and Immunology , University of Muenster , Münster , Germany.

PMID: 28266235
DOI: 10.1080/03009742.2017.1288827

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Acute-Phase Proteins / analysis
Antibodies, Monoclonal / administration & dosage*
Antibodies, Monoclonal, Humanized
Arthritis, Juvenile* / blood
Arthritis, Juvenile* / diagnosis
Arthritis, Juvenile* / drug therapy
Arthritis, Juvenile* / physiopathology
Biomarkers / blood
Calgranulin A / blood*
Calgranulin B / blood*
Child, Preschool
Drug Monitoring / methods
Female
Humans
Immunologic Factors / administration & dosage
Interleukin-18 / blood*
Interleukin-1beta / antagonists & inhibitors
Macrophage Activation
Male
Treatment Outcome

Substances

Acute-Phase Proteins
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Biomarkers
Calgranulin A
Calgranulin B
Immunologic Factors
Interleukin-18
Interleukin-1beta
canakinumab